]>
IRCT20201108049309N1 IRCT 2022-06-07 Shiraz University of Medical Sciences Effect of Metformin in Acne Vulgaris Evaluation of the effectiveness of Metformin in comparison with Doxycycline in treatment of patients with Acne Vulgaris skin disease. 2020-12-14 anticipated 40 Complete https://irct.ir/trial/52843 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: All details and explanation are written in specific part, Randomization description: Metformin and Doxycline will be put in alike boxes and by using sealed envelope online system block randomization will be done and the code of block randomization will be put on the boxes. drugs will be given to the participants monthly and the codes will not be clarified until the end of research (allocation concealment), Blinding description: Due to the different forms of drugs, patients and clinical caregivers who deliver drugs to patients are not blind. But the clinical assessor blind to how patients intervene. 3 Acne. Intervention 1: Intervention group: Intervention group: Apometformin 500 mg twice daily+ topical benzoyl peroxide 5% (pangel) on the lesions every other night for 2 months. Intervention 2: Control group: Doxycycline (Hakim company) 100 mg daily for 2 months + benzoyl proxide 5%gel(pangel) every other night on acne lesions ; the Intervention group: Metformin (Abidi Company) 500mg daily for 2 months +benzoyl proxide 5%gel(pangel) every other night on acne lesions. Yes - There is a plan to make this available What will be shared: Demographic data and the result of the clinical trial When: One year later To whom: Researchers Conditions: After the publication of the extracted article of the clinical Where to obtain: Sending Email to the researchers How to obtain: Sending the request via the email Comments:
public Nazafarin Yazdanpanah
Shiraz, Zand street, Shahid faghihi hospital, floor 3, Dermatology Department
Shiraz Iran (Islamic Republic of) 7134846114 +98 71 3231 9049 Nazafarin.yazdanpanah@gmail.com Shiraz University of Medical Sciences scientific Nazafarin Yazdanpanah
Shiraz, Zand street, Shahid faghihi hospital, floor 3, Dermatology Department
Shiraz Iran (Islamic Republic of) 7134846114 +98 71 3231 9049 Nazafarin.Yazdanpanah@gmail.com Shiraz University of Medical Sciences Iran (Islamic Republic of) 16-40 years old patients with moderate acne . They should not have been treated with systemic medications since 1 month ago. They should not have been treated with topical therapy since 2 weeks ago. 16 years 40 years Both The patients with a history of hypersensitivity to metformin and doxycycline. . Patients with systemic diseases are excluded. The patients with systemic disease The pregnant and lactating women L70.9 Acne, unspecified Treatment - Drugs Treatment - Drugs Intervention group: Intervention group: Apometformin 500 mg twice daily+ topical benzoyl peroxide 5% (pangel) on the lesions every other night for 2 months Control group: Doxycycline (Hakim company) 100 mg daily for 2 months + benzoyl proxide 5%gel(pangel) every other night on acne lesions ; the Intervention group: Metformin (Abidi Company) 500mg daily for 2 months +benzoyl proxide 5%gel(pangel) every other night on acne lesions Acne severity. Timepoint: before treatment and 1,2 months after treatment. Method of measurement: Global acne grading system,burke and cunliffe and counting total lesion count. Response to treatment. Timepoint: at the onset and 2 months after treatment. Method of measurement: asking patient himself. Effect of acne on patient life. Timepoint: before treatment and 2 months after treatment. Method of measurement: Cardiff Acne disability index method. Shiraz University of Medical Sciences Approved 2020-12-12 Ethics Committee of Shiraz University of Medical Sciences Shiraz, Zand Ave, medical university, ethics comittee Shiraz Fars Iran (Islamic Republic of)